基于体积指标的[18F]FDG PET/CT监测IgG4相关疾病活动度与治疗反应
本研究纳入17例IgG4相关疾病患者,在治疗前及治疗中行[18F]FDG PET/CT,以SUV≥2.5为固定阈值勾画病灶边界,计算总MTV和总TLG。结果显示受累器官数、总MTV和总TLG与血清IgG4及sIL-2R显著相关,且治疗中SUVmax、总MTV和总TLG均较治疗前显著降低。
要点
- 总MTV和总TLG与血清IgG4及sIL-2R水平显著相关。
- 治疗中SUVmax、总MTV和总TLG均较治疗前显著降低。
- PET/CT体积指标可用于评估多器官受累范围并监测治疗。
核心结论
- [18F]FDG PET/CT体积指标有助于评估IgG4-RD治疗前多器官受累范围并监测治疗反应。
研究设计与样本
- 研究纳入17例IgG4-RD患者,在治疗前及治疗中行[18F]FDG PET/CT检查。
- 以SUV≥2.5为固定阈值确定病灶边界,计算总MTV和总TLG。
主要发现
- 每例患者平均受累器官数为3.8个,由[18F]FDG摄取确定。
- 受累器官数与IgG4相关(P=0.046),与sIL-2R相关(P<0.001)。
- 总MTV与IgG4相关(P<0.001),与sIL-2R相关(P=0.031)。
- 总TLG与IgG4相关(P<0.001),与sIL-2R相关(P=0.031)。
- 治疗中SUVmax、总MTV和总TLG均显著低于治疗前(均P<0.001)。
关键数值与推荐
- 病灶边界采用SUV≥2.5的固定阈值确定。
- 按临床评估,所有患者均分类为改善。
临床怎么用
- 可在治疗前用[18F]FDG PET/CT体积指标评估IgG4-RD多器官受累范围。
- 可在治疗中用SUVmax、总MTV和总TLG监测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The efficiency of [18F]FDG PET/CT using volume-based indices was evaluated to assess the disease activity and response to therapy in patients with immunoglobulin G4-related disease (IgG4-RD). METHODS: A total of 17 patients with IgG4-RD were examined with [18F]FDG PET/CT before and during treatment. The lesion boundary was determined using a fixed threshold of standardized uptake value (SUV) ≥ 2.5. The highest maximum SUV (SUVmax) among all affected lesions was calculated for individual patients. We summed metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of each affected lesion to generate a total MTV and total TLG. PET results were compared with those of serum IgG4 and soluble interleukin-2 receptor (sIL-2R) levels. RESULTS: The mean number of involved organs per patient was 3.8 as determined by [18F]FDG uptake. The number of involved organs, total MTV and total TLG were significantly correlated with IgG4 (P = 0.046, < 0.001, < 0.001, respectively) and sIL-2R (P < 0.001, = 0.031, 0.031, respectively). According to the clinical assessments for therapy response, all patients were classified as improved. The SUVmax, total MTV, and total TLG during therapy were all significantly lower than those before therapy (all P < 0.001). CONCLUSION: [18F]FDG PET/CT is valuable for assessing the extent of multi-organ involvement before therapy and monitoring subsequent therapy in patients with IgG4-RD. [18F]FDG PET/CT using volumetric indices correlated with serum IgG4 and sIL-2R levels.
引用
- Mitamura K, Arai-Okuda H, Yamamoto Y, et al. Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease. EJNMMI Res. 2020. PMID: 33296037. doi:10.1186/s13550-020-00743-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。